> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Nurtec ODT
- URL: https://www.fdaweb.com/regulatory-review-period-for-nurtec-odt/
- Published: 2022-09-23T12:00:00.000Z
- Updated: 2026-09-14T18:00:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152806

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Biohaven Pharmaceutical’s Nurtec ODT (rimegepant sulfate), indicated for the acute treatment of migraine with or without aura in adults. The regulatory review period period is 3,390 days, of which 3,144 days occurred during the testing phase and 246 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-09-23/pdf/2022-20634.pdf?ref=fdaweb.com).